Thymus and activation-regulated chemokine (TARC) as treatment response marker for paediatric Hodgkin lymphoma: A pilot study

Eline A. M. Zijtregtop; Claudius Diez; C. Michel Zwaan; Margreet A. Veening; prinses maxima; Friederike A. G. Meyer-Wentrup

doi:10.1111/bjh.18473

Thymus and activation-regulated chemokine (TARC) as treatment response marker for paediatric Hodgkin lymphoma: A pilot study

Eline A. M. Zijtregtop, Claudius Diez, C. Michel Zwaan, Margreet A. Veening, prinses maxima^*, Friederike A. G. Meyer-Wentrup

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Article › Academic › peer-review

7 Citations (Scopus)

88 Downloads (Pure)

Abstract

Classical Hodgkin lymphoma (cHL) is characterised by malignant Hodgkin Reed-Sternberg cells located in an inflammatory microenvironment. Blood biomarkers result from active cross-talk between malignant and non-malignant cells. One promising biomarker in adult patients with cHL is thymus and activation-regulated chemokine (TARC). We investigated TARC as marker for interim and end-of-treatment response in paediatric cHL. In this multicentre prospective study, TARC levels were measured among 99 paediatric patients with cHL before each cycle of chemotherapy and were linked with interim and end-of-treatment remission status. TARC levels were measured by enzyme-linked immunosorbent assay. At diagnosis, TARC levels were elevated in 96% of patients. Plasma TARC levels declined significantly after one cycle of chemotherapy (p < 0.01 vs. baseline) but did not differ at interim assessment by positron emission tomography (p = 0.31). In contrast, median plasma TARC at end of treatment was significantly higher in three patients with progressive disease compared to those in complete remission (1.226 vs. 90 pg/ml; p < 0.001). We demonstrate that, in paediatric patients, plasma TARC is a valuable response marker at end-of-treatment, but not at interim analysis after the first two chemotherapy cycles. Further research is necessary to investigate TARC as marker for long-term progression free survival.

Original language	English
Pages (from-to)	70-78
Number of pages	9
Journal	British Journal of Haematology
Volume	200
Issue number	1
Early online date	20 Sept 2022
DOIs	https://doi.org/10.1111/bjh.18473
Publication status	Published - Jan 2023

Bibliographical note

Funding Information:
This work was financially supported by the Ferenc Foundation and the Erasmus MC Foundation, enabled by a legacy of the family Etienne‐van Dijk. We would like to thank them both. The funding source was not involved on the study design, data collection, data analysis, interpretation of data, writing the report or the decision to submit the paper for publication. The visual abstract was created with BioRender.com

Publisher Copyright:
© 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

Access to Document

10.1111/bjh.18473Licence: CC BY-NC-ND

Br J Haematol - 2022 - Zijtregtop - Thymus and activation‐regulated chemokine TARC as treatment response marker forFinal published version, 543 KBLicence: CC BY-NC-ND

Cite this

@article{d89e960d18a54c988aba324b1b6ed3e1,

title = "Thymus and activation-regulated chemokine (TARC) as treatment response marker for paediatric Hodgkin lymphoma: A pilot study",

abstract = "Classical Hodgkin lymphoma (cHL) is characterised by malignant Hodgkin Reed-Sternberg cells located in an inflammatory microenvironment. Blood biomarkers result from active cross-talk between malignant and non-malignant cells. One promising biomarker in adult patients with cHL is thymus and activation-regulated chemokine (TARC). We investigated TARC as marker for interim and end-of-treatment response in paediatric cHL. In this multicentre prospective study, TARC levels were measured among 99 paediatric patients with cHL before each cycle of chemotherapy and were linked with interim and end-of-treatment remission status. TARC levels were measured by enzyme-linked immunosorbent assay. At diagnosis, TARC levels were elevated in 96% of patients. Plasma TARC levels declined significantly after one cycle of chemotherapy (p < 0.01 vs. baseline) but did not differ at interim assessment by positron emission tomography (p = 0.31). In contrast, median plasma TARC at end of treatment was significantly higher in three patients with progressive disease compared to those in complete remission (1.226 vs. 90 pg/ml; p < 0.001). We demonstrate that, in paediatric patients, plasma TARC is a valuable response marker at end-of-treatment, but not at interim analysis after the first two chemotherapy cycles. Further research is necessary to investigate TARC as marker for long-term progression free survival.",

author = "Zijtregtop, {Eline A. M.} and Claudius Diez and Zwaan, {C. Michel} and Veening, {Margreet A.} and prinses maxima and Meyer-Wentrup, {Friederike A. G.}",

note = "Funding Information: This work was financially supported by the Ferenc Foundation and the Erasmus MC Foundation, enabled by a legacy of the family Etienne‐van Dijk. We would like to thank them both. The funding source was not involved on the study design, data collection, data analysis, interpretation of data, writing the report or the decision to submit the paper for publication. The visual abstract was created with BioRender.com Publisher Copyright: {\textcopyright} 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.",

year = "2023",

month = jan,

doi = "10.1111/bjh.18473",

language = "English",

volume = "200",

pages = "70--78",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley & Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Thymus and activation-regulated chemokine (TARC) as treatment response marker for paediatric Hodgkin lymphoma

T2 - A pilot study

AU - Zijtregtop, Eline A. M.

AU - Diez, Claudius

AU - Zwaan, C. Michel

AU - Veening, Margreet A.

AU - maxima, prinses

AU - Meyer-Wentrup, Friederike A. G.

N1 - Funding Information: This work was financially supported by the Ferenc Foundation and the Erasmus MC Foundation, enabled by a legacy of the family Etienne‐van Dijk. We would like to thank them both. The funding source was not involved on the study design, data collection, data analysis, interpretation of data, writing the report or the decision to submit the paper for publication. The visual abstract was created with BioRender.com Publisher Copyright: © 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

PY - 2023/1

Y1 - 2023/1

N2 - Classical Hodgkin lymphoma (cHL) is characterised by malignant Hodgkin Reed-Sternberg cells located in an inflammatory microenvironment. Blood biomarkers result from active cross-talk between malignant and non-malignant cells. One promising biomarker in adult patients with cHL is thymus and activation-regulated chemokine (TARC). We investigated TARC as marker for interim and end-of-treatment response in paediatric cHL. In this multicentre prospective study, TARC levels were measured among 99 paediatric patients with cHL before each cycle of chemotherapy and were linked with interim and end-of-treatment remission status. TARC levels were measured by enzyme-linked immunosorbent assay. At diagnosis, TARC levels were elevated in 96% of patients. Plasma TARC levels declined significantly after one cycle of chemotherapy (p < 0.01 vs. baseline) but did not differ at interim assessment by positron emission tomography (p = 0.31). In contrast, median plasma TARC at end of treatment was significantly higher in three patients with progressive disease compared to those in complete remission (1.226 vs. 90 pg/ml; p < 0.001). We demonstrate that, in paediatric patients, plasma TARC is a valuable response marker at end-of-treatment, but not at interim analysis after the first two chemotherapy cycles. Further research is necessary to investigate TARC as marker for long-term progression free survival.

AB - Classical Hodgkin lymphoma (cHL) is characterised by malignant Hodgkin Reed-Sternberg cells located in an inflammatory microenvironment. Blood biomarkers result from active cross-talk between malignant and non-malignant cells. One promising biomarker in adult patients with cHL is thymus and activation-regulated chemokine (TARC). We investigated TARC as marker for interim and end-of-treatment response in paediatric cHL. In this multicentre prospective study, TARC levels were measured among 99 paediatric patients with cHL before each cycle of chemotherapy and were linked with interim and end-of-treatment remission status. TARC levels were measured by enzyme-linked immunosorbent assay. At diagnosis, TARC levels were elevated in 96% of patients. Plasma TARC levels declined significantly after one cycle of chemotherapy (p < 0.01 vs. baseline) but did not differ at interim assessment by positron emission tomography (p = 0.31). In contrast, median plasma TARC at end of treatment was significantly higher in three patients with progressive disease compared to those in complete remission (1.226 vs. 90 pg/ml; p < 0.001). We demonstrate that, in paediatric patients, plasma TARC is a valuable response marker at end-of-treatment, but not at interim analysis after the first two chemotherapy cycles. Further research is necessary to investigate TARC as marker for long-term progression free survival.

UR - http://www.scopus.com/inward/record.url?scp=85138363680&partnerID=8YFLogxK

U2 - 10.1111/bjh.18473

DO - 10.1111/bjh.18473

M3 - Article

C2 - 36128637

SN - 0007-1048

VL - 200

SP - 70

EP - 78

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 1

ER -

Thymus and activation-regulated chemokine (TARC) as treatment response marker for paediatric Hodgkin lymphoma: A pilot study

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this